Department of Internal Medicine I, Goethe University, Frankfurt, Germany.
Department of General and Visceral Surgery, University Hospital, Goethe University, Frankfurt, Germany.
Transpl Int. 2022 Mar 17;35:10108. doi: 10.3389/ti.2022.10108. eCollection 2022.
Acute-on-chronic liver failure (ACLF) is a distinct clinical syndrome, characterized by acute decompensation (AD) of liver cirrhosis, severe systemic inflammation, intra- and extrahepatic organ failures, and a high short-term mortality. Liver transplantation (LT) is a potentially life-saving treatment for patients with decompensated liver cirrhosis and, due to the high mortality rates, particularly for ACLF patients. In the last decade, a plethora of studies has produced compelling evidence in favor of LT in ACLF, demonstrating high post-LT survival rates and excessive waitlist mortality. The importance of LT in these patients is underscored by the fact that no specific therapy for ACLF is available yet, rendering expeditious life-saving LT to be the only feasible treatment option for some ACLF patients. This review aims to provide an overview on pathophysiology, clinical trajectory, and clinical management of ACLF and to delineate the current literature regarding perspectives and limitations of LT as a life-saving treatment option for ACLF patients.
急性慢性肝衰竭(ACLF)是一种独特的临床综合征,其特征为肝硬化的急性失代偿(AD)、严重的全身炎症、肝内外器官衰竭,以及短期死亡率高。肝移植(LT)是治疗失代偿性肝硬化患者的一种潜在救生治疗方法,由于死亡率高,特别是 ACLF 患者的死亡率高。在过去十年中,大量研究提供了支持 ACLF 中 LT 的有力证据,证明了 LT 后的高存活率和过度等待名单死亡率。LT 在这些患者中的重要性体现在目前尚无针对 ACLF 的特定治疗方法,因此迅速进行救生 LT 是一些 ACLF 患者唯一可行的治疗选择。本综述旨在概述 ACLF 的病理生理学、临床轨迹和临床管理,并阐述关于 LT 作为 ACLF 患者救生治疗选择的观点和局限性的当前文献。